Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy

Abstract Background To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y12 receptor inhibitor. Clopidogrel is a prodrug requiring activation by the cytochrome P450 enzy...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Abdullah M. Al-Rubaish, Fahad A. Al-Muhanna, Abdullah M. Alshehri, Mohammed A. Al-Mansori, Rudaynah A. Alali, Rania M. Khalil, Khalid A. Al Faraidy, Cyril Cyrus, Mohammed M. Sulieman, Chittibabu Vatte, Daniel M. F. Claassens, Jurriën M. ten Berg, Folkert W. Asselbergs, Amein K. Al-Ali
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2020-06-01
Edice:BMC Cardiovascular Disorders
Témata:
Clopidogrel
Ticagrelor
Prasugrel
Platelet aggregation inhibitor
King Fahd hospital
Purinergic P2 receptor antagonists
On-line přístup:http://link.springer.com/article/10.1186/s12872-020-01558-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky